Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease

[1]  J. Mathis,et al.  Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: Results from a multi‐center, randomized, active controlled trial , 2007, Movement disorders : official journal of the Movement Disorder Society.

[2]  P. O'Suilleabhain,et al.  Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease. , 2007, Archives of neurology.

[3]  H. Reichmann,et al.  Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: A reader‐blinded monocenter echocardiography study , 2007, Movement disorders : official journal of the Movement Disorder Society.

[4]  A. Antonini,et al.  Valvular heart disease and the use of dopamine agonists for Parkinson's disease. , 2007, The New England journal of medicine.

[5]  B. Roth.  Drugs and valvular heart disease. , 2007, The New England journal of medicine.

[6]  W. Haverkamp,et al.  Dopamine agonists and the risk of cardiac-valve regurgitation. , 2007, The New England journal of medicine.

[7]  E. Chung,et al.  Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists , 2006, Movement disorders : official journal of the Movement Disorder Society.

[8]  E. Wolf,et al.  Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study , 2006, Movement disorders : official journal of the Movement Disorder Society.

[9]  R. Horowski,et al.  Lisuride, a Dopamine Receptor Agonist With 5-HT2B Receptor Antagonist Properties: Absence of Cardiac Valvulopathy Adverse Drug Reaction Reports Supports the Concept of a Crucial Role for 5-HT2B Receptor Agonism in Cardiac Valvular Fibrosis , 2006, Clinical neuropharmacology.

[10]  P. Rochon,et al.  Cardiac Valvulopathy Associated with Pergolide Use , 2006, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[11]  T. Nakayama,et al.  Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. , 2006, Neurology.

[12]  P. Marcos-Alberca,et al.  Cabergoline-related severe restrictive mitral regurgitation. , 2005, The New England journal of medicine.

[13]  Johannes Schwarz,et al.  High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias. , 2005, Parkinsonism & related disorders.

[14]  K. Chaudhuri,et al.  Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson’s disease patients treated with cabergoline , 2005, Journal of Neural Transmission.

[15]  Patrick Santens,et al.  Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease , 2004, The Lancet.

[16]  A. Berardelli,et al.  Dual dopamine agonist treatment in Parkinson’s disease , 2003, Journal of Neurology.

[17]  V. Setola,et al.  3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. , 2003, Molecular pharmacology.

[18]  T. Müller,et al.  Fibrosis associated with dopamine agonist therapy in Parkinson's disease. , 2003, Clinical neuropharmacology.

[19]  D. Gilbert,et al.  Tic reduction with pergolide in a randomized controlled trial in children , 2003, Neurology.

[20]  B. Roth,et al.  Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications , 2000, Circulation.

[21]  B. Largent,et al.  Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. , 2000, Molecular pharmacology.

[22]  O. Rascol,et al.  A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. , 1994, Journal of neurology, neurosurgery, and psychiatry.